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E-mail: iris.behrmann@uni.luInterleukin-6 (IL-6)-type cytokines share the common receptor
glycoprotein 130 (gp130), which activates a signaling cascade
involving Janus kinases (JAKs) and signal transducer and
activator of transcription (STAT) transcription factors. IL-6
and/or its signaling pathway is often deregulated in diseases,
such as chronic liver diseases and cancer. Thus, the identifica-
tion of compounds inhibiting this pathway is of interest
for future targeted therapies. We established novel cellular
screening systems based on a STAT-responsive reporter gene
(Cypridina luciferase). Of a library containing 538 microRNA
(miRNA)mimics, several miRNAs affected hyper-IL-6-induced
luciferase activities. When focusing on candidate miRNAs spe-
cifically targeting 30 UTRs of signaling molecules of this
pathway, we identified, e.g., miR-3677-5p as a novel miRNA
affecting protein expression of both STAT3 and JAK1, whereas
miR-16-1-3p, miR-4473, and miR-520f-3p reduced gp130 sur-
face expression. Interestingly, combination treatment with 2 or
3 miRNAs targeting gp130 or different signaling molecules of
the pathway did not increase the inhibitory effects on phospho-
STAT3 levels and STAT3 target gene expression compared to
treatment with single mimics. Taken together, we identified a
set of miRNAs of potential therapeutic value for cancer and
inflammatory diseases, which directly target the expression of
molecules within the IL-6-signaling pathway and can dampen
inflammatory signal transduction.
INTRODUCTION
The inflammatory cytokine interleukin-6 (IL-6) signals via a receptor
complex consisting of IL6R (IL6Ra, gp80) and the signaling subunit
glycoprotein 130 (gp130) (IL6Rb, IL6ST), shared among all IL-6-type
cytokines. gp130-associated Janus kinase 1 (JAK1) phosphorylates
different tyrosine residues in the cytoplasmic tail of gp130, to which
mainly signal transducer and activator of transcription 3 (STAT3)
transcription factors are recruited. Upon phosphorylation, STATs
translocate into the nucleus and regulate the expression of various
genes, including the one encoding suppressor of cytokine signaling
3 (SOCS3), an important negative regulator of this pathway.1 Next
to this classical signaling pathway triggered by membrane IL6R-
gp130 complexes, IL-6 can also act on cells, which do not expressMolecular T
This is an open access article under the CC BY-NC-IL6R (but only gp130) when complexed to a soluble form of IL6R
(sIL6R), a process termed trans-signaling.2
In addition to its manifold physiological roles, e.g., in the immune
system and in liver regeneration,3,4 IL-6 has important systemic
and local effects in the pathogenesis of cancers, such as multiple
myeloma, endometrial cancer, lung cancer, colorectal cancer, renal
cell carcinoma, cervical cancer, breast cancer, and ovarian carci-
noma.5,6 IL-6 is important for tumor development and angiogenesis,
affecting the proliferation, migration, and invasion of cells, as well as
for protecting them against drug treatments and apoptosis.5,6 Tumor-
induced systemic IL-6 can induce systemic metabolic changes, e.g.,
lipolysis in the white adipose tissue and insulin resistance of the
skeletal muscle, which may ultimately lead to cancer inflammation-
induced cachexia (reviewed in White7). In addition, IL-6 can act
locally in the tumor on immune cells to suppress anti-cancer immu-
nity.8,9 For example, IL-6 favors the development of M2macrophages
and myeloid-derived suppressor cells (MDSCs), leading to increased
levels of immunosuppressive factors such as IL-10 and IL-4, while it
attenuates the differentiation of Th1 cells. Tumor-associated macro-
phages have also been described to produce IL-6, thus promoting
the expansion of hepatocellular carcinoma (HCC) stem cells and,
therefore, tumorigenesis.10
IL-6 plays an important role in HCC, the focus of this study. IL-6 and
sIL6R levels have been shown to be increased in the sera of patients
with HCC,11 and high levels of serum IL-6 can serve as a biomarker
for an elevated risk to develop HCC.12 Increased activity of STAT3
was observed in liver tumors of mice treated with N-nitrosodiethyl-
amine (DEN);13 later, IL-6 was found to be crucially implicated in
this HCC mouse model,14,15 which, according to gene expressionherapy: Nucleic Acids Vol. 16 June 2019 ª 2019 The Author(s). 419
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Molecular Therapy: Nucleic Acidsdata, best resembles liver cancer with poor prognosis in humans.16 Au-
tocrine production of IL-6 by liver cancer progenitor cells also contrib-
utes to their malignant progression.17 While liver-specific knockout of
SOCS3 promoted DEN-induced hepatocarcinogenesis,18,19 deletion of
gp130 or STAT3 reduced HCC prevalence and resulted in smaller
tumors in DEN-treated mice.15,20 Similarly, in another chemically
induced HCC mouse model (thioacetamide based), the absence of
STAT3 in liver parenchymal cells attenuated HCC development.21
Interestingly, IL-6-trans-signaling, rather than classical signaling,
seems to be responsible for DEN-dependent tumor development.22,23
Of note, a whole-genome sequencing study of 88 matched pairs of
(hepatitis B virus [HBV]-related) HCC tumor and surrounding tissues
indicated that the (IL-6)-JAK-STAT-signaling pathway is a major
oncogenic driver in HCC, with mutations in almost half of the cases
investigated, including IL6R gene amplifications in 26% of the samples
and (in part, gain-of-function) mutations in the JAK1 gene in 9.1%.24
Altogether, these data strongly suggest an important role of IL-6
signaling in the initiation and development of HCC, and they have
spawned the interest of targeting molecules involved in the IL-6-
JAK-STAT3-signaling pathway as a strategy to block STAT3 activa-
tion.25–27 Compounds targeting IL-6-STAT3 signaling have been
reported to suppress the transformed phenotype and tumor progres-
sion.5,6 For example, treatment with antisense oligonucleotides
(ASOs) targeting STAT3 leads to an inhibition of proliferation of
various hepatoma cell lines, a reduction of tumor size, and an
improved survival of mice bearing orthotopically xenografted
HCC.28 Interestingly, STAT3 ASO therapy has entered clinical trials,
yielding the first promising results particularly for the treatment of
lymphoma and lung cancer.29 Other studies on hepatoma describe
stronger effects of anti-cancer drugs when this pathway is concomi-
tantly targeted, pointing at the anti-apoptotic effects of JAK-STAT3
signaling and its implication in drug resistance.26,30
MicroRNAs (miRNAs) have been recognized as promising drug can-
didates (miRNA replacement therapy) as well as drug targets (e.g., of
anti-miRNAs), and nucleic acid-based therapeutic approaches are
particularly promising if the target organ is the liver.31–33 Therefore,
we aimed to identify miRNAs that can modulate the IL-6-JAK1-
STAT3-signaling pathway in hepatoma cells. To do so, we established
2 novel functional cellular screening systems, which allowed for the
selection of miRNAs affecting expression of STAT3-responsive re-
porter genes. Of a library of 538 mimics, we identified a set of
miRNAs targeting 30 UTR sequences of the main signaling molecules
of the pathway. Further characterization revealed their effects on
STAT3 or JAK1 protein expression, on gp130 surface availability,
as well as on cytokine-mediated signaling events.
RESULTS
Two Novel Cellular High-Throughput Screening Systems
Identify Candidate miRNAs as Modulators of the IL-6-JAK-
STAT3-Signaling Pathway
To identify miRNAs that regulate the IL-6-JAK-STAT3-signaling
pathway, we first performed a pre-screen of a miRNA mimic-based420 Molecular Therapy: Nucleic Acids Vol. 16 June 2019library in HEK293T reporter cells (whose growth is not affected by
IL-6 signaling), engineered to express the secreted Cypridina lucif-
erase gene under the control of 6 (synthetic) STAT3-responsive ele-
ments (see Figure S1 for a schematic flowchart of this study). Since
sIL6R is known to be upregulated in HCC and IL-6 trans-signaling
has been implied in HCC,11,23 we stimulated the cells with hyper-
IL-6 (hy-IL-6) to detect miRNAs, which modulate the signaling inde-
pendently of the membrane-bound IL6R (hy-IL-6 is a designer cyto-
kine composed of sIL6R linked to IL-634).
From 538 molecules tested (see Table S1), 129 miRNA candidates,
which either increased or decreased luciferase activity without a
major effect on growth (data not shown), were retained for the screen
in the hepatoma cell line Hep3B. The latter was engineered to express
the secreted Cypridina luciferase gene under the control of a highly
IL-6-inducible STAT3-specific rat pancreatitis-associated protein 1
(rPAP1) promoter35,36 (Figure S2). miRNA candidates were selected
based on a reduction or increase in the luciferase activity, normalized
to the negative control mimic (NMC) as well as to the viability of the
Hep3B reporter cells (Figure S3; it should be noted that hy-IL-6 does
not stimulate Hep3B cell proliferation). Based on this analysis, 34
miRNA mimics were selected to be further studied regarding their
ability to modulate phosphorylation and, thus, activation of STAT3.
These included miR-124-3p and miR-142-3p, previously shown to
target molecules involved in the JAK-STAT pathway (STAT3,37
IL6R,38 and gp130,39 respectively), thus serving as positive controls.
Effect of Selected miRNAs on Endogenous pSTAT3 and STAT3
Levels following Cytokine Stimulation
In the previous screening approaches, miRNA candidates were iden-
tified, which affected the IL-6-signaling cascade. To further refine this
list of interesting miRNAs, the phosphorylation of STAT3 (as func-
tional readout) and total STAT3 (as potential target) were quantified
by western blot analysis in Hep3B cells transfected with each of the 34
miRNA mimics and stimulated with hy-IL-6 (Figure 1). miR-142-3p,
a miRNA known to target gp130, the common signaling receptor for
all IL-6-type cytokines, only slightly decreased phosphorylated (p)
STAT3 and STAT3 levels (Figure 1). The other control, miR-124-
3p, reduced the expression level of STAT3 by 50%, as previously pub-
lished,37 but it had no effect on pSTAT3, in line with the finding that
only a part of STAT3 proteins generally becomes phosphorylated
following cytokine stimulation.40 Based on their potential to reduce
pSTAT3 and/or STAT3 levels, 15 candidate miRNAs were selected
for the identification of their putative target(s) by luciferase-30 UTR
reporter assays (in bold and marked with a star, Figure 1; some can-
didates, such as miR-155-5p, were not taken along as they have been
extensively studied;41 see also Figure 6).
Identification of miRNA Mimics Reducing gp130 Surface
Availability
Next, we were interested to screen for miRNAs that specifically and
directly target gp130. To do so, luciferase reporter assays were per-
formed using plasmids harboring the cDNA for Gaussia luciferase,
a secreted enzyme, followed by 30 UTR sequences of gp130. As the
Figure 1. Effect of Selected miRNAs on STAT3 and
pSTAT3 Protein Levels
Hep3B cells were transfected with 34 selected mimics and
2 days later stimulated for 24 h with hy-IL-6 to activate the
JAK-STAT pathway. pSTAT3 and STAT3 protein levels
were quantified using the LI-COR device and normalized to
total protein staining (data not shown). The normalized
signal obtained for each sample was divided by the signal
obtained for the transfection control (HiPerFect). Vinculin
staining is shown as an additional control. Error bars
represent the SD of 3 biological replicates. Mimics selected
for luciferase-30 UTR reporter assays are in bold and
marked with a star. A representative western blot result for
pSTAT3, STAT3, and Vinculin is shown.
www.moleculartherapy.org30 UTR of the gene encoding gp130 is very long (6,001 bp), 3 different
plasmids with separate, overlapping parts of the gp130 30 UTR were
constructed (Figure 2A). HEK293T cells were used for the
co-transfection experiments as they can be better transfected than
liver-derived cells, thereby providing a smaller variability between
the biological replicates.
After a first, preliminary experiment with all 15 miRNA candidates
(data not shown), 10 were further evaluated for their binding to the
gp130 30 UTR sequence: miR-16-1-3p, miR-205-3p, miR-4473,
and miR-520f-3p reproducibly decreased the luciferase activity of
the respective gp130 30 UTR plasmid by more than 50% (gp130a,
Figure 2B). Similarly, miR-194-5p and miR-584-5p as well as
miR-382-5p and miR-4473 reduced the luciferase activity of the
plasmids harboring the part b or c, respectively, by at least 40%
(Figure 2B). No off-target effects of these miRNA mimics were found
in control experiments using only the backbone vector (Figure S4).
In total, 7 different miRNA mimics (miR-16-1-3p, miR-194-5p,
miR-205-3p, miR-382-5p, miR-4473, miR-520f-3p, and miR-
584-5p, depicted in gray in Figure 2B) had a strong effect on gp130
30 UTR.MolecularAs IL-6 (classical or trans-) signaling is initiated
from gp130 receptors present at the plasma
membrane, we evaluated the effects of selected
miRNAs on the surface expression of endoge-
nous gp130 by flow cytometry in different cell
lines from various tissues. In comparison to
the cells transfected with NCM1 (in gray),
miR-16-1-3p, miR-194-5p, miR-4473, and
miR-520f-3p decreased gp130 surface expres-
sion in both Hep3B hepatoma cells (Figure 2C)
and non-transformed PH5CH8 liver cells (Fig-
ure 2D). Two miRNAs had cell-specific effects:
miR-382-5p reduced gp130 surface expression
only in Hep3B cells, while miR-584-5p affected
gp130 surface expression (relative to the
NCM1 control) only in PH5CH8 cells (Fig-
ures S5A and S5B). Finally, miR-205-3p had
almost no effects on the gp130 levels in bothtested liver cell lines (Figures S5A and S5B), although it had clear ef-
fects in the reporter gene assays.
miR-16-1-3p, miR-4473, and miR-520f-3p were further tested in a
variety of other cells types, such as lung adenocarcinoma (A549),
prostate carcinoma (DU145), HEK293T, and melanoma cells
(IGR39). Upon transfection of each miRNA tested (orange), histo-
grams were strongly shifted to the left in comparison to control
cells (Figures 2E–2H), indicating that these 3 miRNAs have a
robust effect on the surface expression of gp130 in a variety of
cells.
miR-16-1-3p, miR-4473, and miR-520f-3p Inhibit hy-IL-6-
Inducible Phosphorylation of STAT3 and Differentially Affect the
Expression of a Target Gene
Surface availability of gp130 has been shown to regulate the cell
responsiveness to IL-6-type cytokines. For example, gp130 expres-
sion is downregulated during granulocyte differentiation42 and
upon activation of T cells.43 Moreover, pre-stimulation with
IL-1b reduces gp130 availability at the surface of human hepato-
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Figure 3. miR-16-1-3p, miR-4473, and miR-520f-3p
Partially Prevent the Activation of STAT3 upon
hy-IL-6 Stimulation by Targeting gp130 mRNA,
Reducing the Expression of a hy-IL-6 Target Gene
in PH5CH8 Cells
Cells were left untreated, reverse transfected with NCM1 or
miR-16-1-3p, miR-4473, and miR-520f-3p mimics (20 nM),
and were stimulated with hy-IL-6 (20 ng/mL). Single mimics
as well as combinations were tested and compared to the
respective NCM1 control (in black). For the double or triple
combinations, 40 or 60 nM NCM1 was used as the
respective control. (A) NormalizedmRNA expression level of
gp130. (B) Representative western blot analysis of both the
activated and total forms of STAT3 and of the Vinculin as
loading control. (C) Normalized mRNA expression level of
Lipopolysaccharide-binding protein (LBP). ThemRNA levels
were monitored upon mimic transfection and hy-IL-6 stim-
ulation (depictedwith dashed lines). Error bars represent the
SD of at least 3 biological replicates. Bottom indicates the
applied treatments per lane.
www.moleculartherapy.orgwe investigated if the effects of miR-16-1-3p, miR-4473, and miR-
520f-3p on gp130 were sufficient to modulate the activation of
STAT3 upon hy-IL-6 stimulation. First of all, we confirmed that
the corresponding miRNA expression level was indeed increased
upon mimic transfection (Figure S6). An only slightly suppressive
effect of the 3 miRNA mimics on gp130 mRNA expression was
observed (Figure 3A), suggesting that translational repression,
rather than mRNA decay, may substantially contribute to gp130
downregulation (for a review, see Iwakawa and Tomari46). Inter-
estingly, all 3 miRNA mimics largely reduced inducible STAT3
phosphorylation in comparison to the NCM1, whereas STAT3
protein levels remained unchanged (single mimics, Figure 3B).
The basal level of STAT3 phosphorylation (i.e., without stimula-
tion) was not affected by any of the 3 mimics (or combinations
thereof), indicating that this “tonic” STAT3 phosphorylationFigure 2. Identification of miRNAs Targeting the Co-receptor gp130 and Affecting Its Surface Availa
(A) Graphic representations of the gp130 30 UTR as well as the predicted binding sites (based on TargetScan w
(B) HEK293T cells were co-transfected with mimics specifically selected for one of the vectors harboring the
sequences of the gene encoding gp130 (gp130a/b/c). Mimics selected for further functional assays are shown in
bars represent the SD of 3 biological replicates. Kruskal-Wallis followed by Dunn’s Post hoc test were performed
and **p < 0.01. (C–H) Selected miRNA candidates affect the surface availability of gp130 in various cell lines. (C
cells, (E) A549 lung adenocarcinoma cells, (F) DU145 prostate cancer cells, (G) HEK293T cells, and (H) IGR39
transfected with a negative control (NCM1, in gray) or one of the selected miRNA mimics and analyzed for gp
miRNAs are depicted in orange, the isotype control is in red, and the transfection control is in blue.
Molecularmay be mediated by signaling events indepen-
dent of gp130 (e.g., elicited by growth factors
or non-IL-6-type cytokines).
To further address the impact of these miRNAs
on a signaling readout, we monitored their effect
on the inducibility of Lipopolysaccharide-binding
protein (LBP), a target gene of IL-6 signaling.47All 3 miRNAs reduced inducible LBP mRNA expression in
PH5CH8 cells; the effect was strongest for miR-16-1-3p, with a reduc-
tion by more than 50% in comparison to the cytokine-stimulated
control cells (Figure 3C). Combination of 2 or all 3 miRNAs had
no additional effect than the one measured for miR-16-1-3p alone.
Of note, miR-4473 and miR-520f-3p, which were less effective in
dampening inducible LBP mRNA expression compared to miR-16-
1-3p, also target the 30 UTR of SOCS3, the major negative regulator
of the pathway (Figure S7A).
IdentificationofmiRNAMimicsDirectlyTargetingJAK1andSTAT3
In similar approaches, we also screened for miRNAs targeting JAK1
and STAT3, 2 other major players of the pathway. In luciferase-30
UTR reporter assays, we identified 8 miRNA candidates (in gray, Fig-
ures 4A and 4C) to be further analyzed for their effects on endogenousbility
ebsite). Sites conserved among mammals are underlined.
Gaussia luciferase cDNA followed by overlapping 30 UTR
gray, and negative control mimic 1 (NCM1) is in white. Error
to assess statistical significance represented with *p < 0.05
) Hep3B hepatoma cells, (D) non-neoplastic PH5CH8 liver
melanoma cells were either left untreated (Ctrl, in purple) or
130 surface expression level by flow cytometry. Candidate

















































































































































































































































































































































































Figure 4. Identification of miRNAs Targeting JAK1
and STAT3 and Affecting Their Endogenous Protein
Levels
(A and C) Graphic representations of (A) JAK1 and (C)
STAT3 30 UTRs as well as predicted binding sites
(TargetScan). Sites conserved among mammals are un-
derlined. HEK293T cells were co-transfected with the
mimics specifically selected for each construct and one of
the vectors harboring theGaussia luciferase cDNA followed
by the 30 UTR of the gene encoding (A) JAK1 or (C) STAT3.
Mimics selected for further functional assays are shown in
gray, and NCM1 is in white. Kruskal-Wallis followed by
Dunn’s post hoc test were performed to assess statistical
significance represented with *p < 0.05, **p < 0.01, and
***p < 0.001. (B and D) Selected miRNAs downregulate
endogenous JAK1 and STAT3 protein levels in PH5CH8
cells. (B) miR-299-3p, miR-3677-5p, and miR-520f-3p
reduce JAK1 protein levels. (D) miR-3677-5p andmiR-506-
3p reduce STAT3 protein levels. A representative western
blot as well as quantifications are depicted. Error bars
represent the SD of at least 3 biological replicates.
Molecular Therapy: Nucleic AcidsJAK1 and/or STAT3 protein levels. To do so, PH5CH8 cells were
transfected with either NCM1 or one of the selected mimics (miR-
194-3p, miR-299-3p, miR-3677-5p, miR-4473, miR-506-3p, miR-
520f-3p, miR-548k, and miR-584-5p).
The 30 UTR of the mRNA encoding JAK1 was found to be strongly
targeted by miR-299-3p, miR-3677-5p, miR-4473, and miR-520f-3p
(Figure 4A). Importantly, of these 4, 3 mimics (miR-299-3p, miR-
520f-3p, and miR-3677-5p) also strongly decreased JAK1 protein
level by approximately 50% (depicted in gray, Figure 4B), while
miR-4473 only had a modest effect.
Regarding STAT3, miR-3677-5p, miR-506-3p, and miR-548k were
identified as mimics targeting its 30 UTR (Figure 4C). STAT3 protein424 Molecular Therapy: Nucleic Acids Vol. 16 June 2019levels in non-neoplastic PH5CH8 cells were
reduced by 50% upon transfection with miR-
3677-5p and miR-506-3p (Figure 4D, depicted
in gray). However, miR-548k had less impact
on STAT3 protein expression (Figure 4D).
Similar findings were observed previously in
Hep3B hepatoma cells (Figure 1C).
Single Mimics Targeting Various Proteins of
the IL-6-Signaling Pathway Attenuate IL-6-
STAT3-Induced Gene Readouts as
Effectively as Combination Treatments
As a next step, we tested whether a combination
of miRNAs with different targets in the IL-6-
signaling pathway would have stronger inhibitory
effects on cytokine signaling compared to single
mimics. For these combinatory experiments, we
selected miR-16-1-3p, miR-299-3p, and miR-124-3p: miR-16-1-3p targets gp130, miR-299-3p targets JAK1 (and
likely IL6R, see Figure S7B), and miR-124-3p targets STAT3 (and
likely IL6R, see Figure S7B) (see Figure 6 for a summary). We now
stimulated with IL-6 (and not with hy-IL-6) so that the potential
effects of a lower IL6R expression would also be reflected in the
results. In this context, we utilized Hep3B cells as they respond better
to IL-6 stimulation than PH5CH8 cells (data not shown).
Figure S8 shows the controls for the efficient transfection of the mimics
as well as their effects on the different target mRNAs. JAK1 mRNA
expression was only affected by miR-299-3p; basal and IL-6-inducible
expression of STAT3 mRNA was attenuated only by miR-124-3p. In
contrast, expression of gp130 was affected not only by miR-16-1-3p
(in line with the previous experiments) but also by miR-299-3p.
A
B
Figure 5. miR-124-3p, miR-16-1-3p, and miR-299-3p
Partially Prevent the Activation of STAT3 upon IL-6
Stimulation by Targeting STAT3, IL6R, gp130, and
JAK1 mRNA, and They Reduce the Induction of the
Expression of IL-6 Target Genes in Hep3B Cells
Cells were left untreated, reverse transfected with NCM1 or
miR-124-3p, miR-16-1-3p, and miR-299-3p mimics
(20 nM), and stimulated with IL-6 (20 ng/mL). Single mimics
as well as combinations were tested and compared to the
respective NCM1 control (in black). For the double or triple
combinations, 40 or 60 nM NCM1 was used as the
respective control. (A) Western blot analysis for both the
activated and total forms of STAT3 and of Vinculin as
loading control. (B) Normalized mRNA expression levels of
LBP, Leucine-rich alpha-2 glycoprotein (LRG1), and
SOCS3 were monitored upon mimic transfection and IL-6
stimulation (depicted with dashed lines). Error bars repre-
sent the SD of at least 3 biological replicates. Bottom in-
dicates the applied treatments per lane.
www.moleculartherapy.orgInterestingly, IL6R mRNA expression was reduced by all 3 mimics,
which was expected for miR-124-3p and miR-299-3p (see Figure S7B),
but not formiR-16-1-3p (miR-299-3p andmiR-16-1-3p had little effect
in the preliminary experiment with reporter plasmids comprising 30
UTR sequences of gp130 or IL6R, respectively; data not shown).
Clear inhibitory effects of all 3miRNAswere observed for the activation
of STAT3 (Figure 5A) aswell as for the IL-6-inducible expression of the
STAT3 target genes LBP, Leucine-rich alpha-2 glycoprotein (LRG1),
and SOCS3 (Figure 5B). Interestingly, combination treatments were
not more effective than single treatments (Figure 5, combinations).
DISCUSSION
In this study, (1) we show that a screen of 538 miRNA mimics de-
signed to identify miRNAs influencing IL-6 (trans-)signaling yielded
a panel of interesting candidate miRNAs affecting the (hyper-)IL-6-Moleculargp130-JAK1-STAT3 pathway. (2) We validated
several selected miRNAs by showing that they
specifically interact with the 30 UTR of the
gp130, JAK1, and/or STAT3 mRNAs. (3) We
confirmed some of those miRNAs to specifically
affect the expression of different proteins in this
pathway, notably, gp130, JAK1, and STAT3. (4)
We found that treatment with single mimics
was as effective in downregulating cytokine
signaling as combinations of multiple miRNA
mimics targeting either gp130 or various mole-
cules in the IL-6-signaling pathway.
As described in the Introduction, IL-6 has impor-
tant systemic and local effects in the pathogenesis
of cancer. It influences tumor development,
angiogenesis, cell proliferation, migration, and
invasion; it has anti-apoptotic and immunomod-ulatory effects.5,6 Previous studies have demonstrated miRNAs as
regulators of the JAK-STAT-signaling pathway. For instance,
miR-124 has been extensively studied and shown to target both
STAT337 and IL6R.38,48 Another example is miR-142-3p, which
was shown to directly target the co-receptor gp130 in cardiac myo-
cytes,39 macrophages,49 and endometrial stromal cells.50
The aim of this study was to identify miRNAs with the potential for
inhibiting the IL-6-JAK-STAT3-signaling pathway and that, there-
fore, might be of therapeutic relevance. Although there are still issues
with miRNA-based therapies (e.g., delivery, poor penetration in tis-
sues, stability, off-target effects; reviewed in Chen),51 the potential
of nucleic acids as versatile drug candidates is more and more recog-
nized.32,33 For example, miRNA-based drugs have been successfully
used in pre-clinical studies (e.g., miR-2652 and anti-miR-1753,54) as
well as in first clinical trials, such as for miR-16-based mimics.55Therapy: Nucleic Acids Vol. 16 June 2019 425
B
A
Figure 6. Summary of the Results Obtained in This Study
(A) Graphical overview of effects of the different miRNAmimics on the IL-6-type cytokine-signaling pathway. For STAT3 phosphorylation, the mimics that reduce the western
blot signal to below 75%or below 50% are listed. For JAK1 and STAT3mimics, those that reduce the western blot signal to below 60% are shown. For gp130, themimics that
reduce surface expression efficiently (below 70%) are listed. The colored dots behind the name of the mimics in the lists indicate additional target genes of the respective
miRNA (red, JAK1; blue, gp130; yellow, STAT3; and green, phosphorylation of STAT3). miRNAs labeled with a “#” have already been characterized before. Interestingly,
downregulation of STAT3 protein alone was never associated with a reduction of phosphorylated STAT3. (B) Summary of the results obtained upon transfection with each of
(legend continued on next page)
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www.moleculartherapy.orgHere we describe and characterize the effects of several novel miRNAs
and of some previously described ones (e.g., miR-124-3p and miR-
506-3p) on the IL-6-signaling pathway (see Figure 6). We focused
on miRNAs that did not affect cell viability, but it would also be
very interesting to further investigate those miRNAs that alter cellular
viability, as previously done for cholangiocarcinoma.56 For example,
the miR-374 family, from which 3 of 6 members were included in the
large library and led to an enhanced cell proliferation (data not
shown), has already been associated with an increased proliferation
and survival, e.g., in gastrointestinal stromal tumors,57 gastric
cancer,58 and hepatoma.59
miRNA-Mediated Effects on STAT3
Interestingly, we noticed that among those miRNAs that most
strongly reduced STAT3 protein levels (miR-124-3p, miR-3677-
5p, and miR-506-3p), only miR-3677-5p reduced pSTAT3 signals
(Figure 1). miR-3677-5p was found to also target JAK1 (see below),
which may explain that this miRNA is more effective on STAT3
phosphorylation than the others. Our results indicate that a reduc-
tion of STAT3 levels by 50% does not translate into decreased
pSTAT3 levels. Indeed, only a fraction of STAT3 is phosphorylated
upon IL-6 stimulation.40 A certain reduction in the expression can
thereby be tolerated without a necessary effect on the absolute
amounts of pSTAT3.
Another interesting aspect of STAT3 silencing is that, in the
absence of STAT3, IL-6 leads to a sustained STAT1 activation60
and switches to an interferon (IFN)g-like response in hepatoma
cells.61 IFNg is one of those cytokines long known to be involved
in anti-tumor defense, since interferon gamma receptor (IFNgR)
and STAT1 deficiency has been described to increase cancer sus-
ceptibility upon treatment with chemical pathogens in mice.62,63
Of note, the observed reduction of STAT3 expression (by 50%)
is not only insufficient to reduce the phosphorylation of STAT3
but also not able to induce a compensatory phosphorylation of
STAT1 (data not shown).
In contrast to our first findings (Figure 1), several studies have
observed a decrease of pSTAT3 signals by miR-124-3p.37,38,48
However, it needs to be taken into consideration that this miRNA
also targets IL6R (seen also in our hands in the luciferase-30
UTR assay [Figure S7B] and confirmed at the mRNA levels [Fig-
ure S8]), which can translate into a reduced signaling input
when analyzing signals elicited by IL-6 (as observed in our final
experiment utilizing IL-6 as a stimulating cytokine; Figure 5).
Since we used the designer cytokine hy-IL-6 for the first experi-
ments, the observed signaling effects were independent of the sur-
face level of IL6R.the 15 selected miRNAs for pSTAT3 (Figure 1, Hep3B), JAK1, and STAT3 (Figure 4, P
luciferase-30 UTR reporter assays (Figures 2, 4, and S7, HEK293T). Results represent th
the control (expressed in %). The SD of at least 3 biological replicates is shown. A d
miR-494-3p, no target could be identified from the ones tested. The list of miRNA effects
in red and increase in green). In addition, the miRNAs are sorted according to their inhmiRNA-Mediated Effects on JAK1
miRNA-mediated downregulation of JAK1 in cancer has been shown
to suppress metastasis and invasion (e.g., miR-214 in lung carci-
noma,64 miR-340 in HCC,65 andmiR-488 in pancreatic ductal adeno-
carcinoma66). We found the 3 miRNAs miR-299-3p, miR-3677-5p,
and miR-520f-3p to diminish JAK1 protein levels by at least 40%.
While JAK1 knockdown only partially inhibits IL-6 signaling, expres-
sion of kinase-deficient mutants of JAK1 totally abolishes IL-6
signaling (unpublished data), indicating that the partial signaling
reduction in the knockdown scenario is due to compensatory binding
of the other JAKs (JAK2 or Tyk2) to gp130. Thus, even a very efficient
downregulation of JAK1 by a miRNA is unlikely to have drastic
effects on IL-6 signaling.
In addition, the downregulation of JAK1 is likely to impact on a
variety of other cytokine signals, as JAK1 is the most promiscuous
Janus kinase from the 4 family members. It is used for the signaling
of the majority of the 40 cytokine receptors. For instance, IFNa/b,
IFNg, and IL-27 signaling, all associated with anti-tumor functions,
are concomitantly reduced when JAK1 is downregulated.61 Inter-
feron-mediated antiviral responses have already been shown to be
impaired by miRNAs targeting JAK1 (e.g., miR-30c67 and miR-
37368). Therefore, it needs to be evaluated whether an inhibition of
JAK1 would be useful in a tumor situation, as IFNs essentially have
anti-tumor effects.69 On the other hand, these miRNAs may be useful
to diminish inflammatory processes involving both IFNs and IL-6-
type cytokines. Similarly, due to their strong anti-inflammatory
effects, JAK inhibitors are regarded as highly promising in inflamma-
tory diseases.70
miR-299-3p was shown to target the 30 UTR of JAK1 and to efficiently
suppress JAK1 mRNA and protein expression (Figures S8C and 4B).
Interestingly, it also affected the 30 UTR of the IL6R (Figure S7B).
Known targets of miR-299-3p include vascular endothelial growth
factor A (VEGFA),71,72 androgen receptor,73 and ATP Binding
Cassette Subfamily E Member 1 (ABCE1),74 which have been linked
to tumor-suppressive functions (less angiogenesis, viability, or drug
resistance). Moreover, miR-299-3p has been shown to be downregu-
lated in The Cancer Genome Atlas (TCGA) HCC tumor samples and
to inhibit growth and invasion of SK-HEP-1 hepatoma cells.75
We also identified miR-3677-5p as a novel miRNA involved in the
regulation of the JAK-STAT pathway. Interestingly, it targets the
expression of both STAT3 and JAK1 with poorly conserved binding
sites present in their 30 UTRs (Figures 4A and 4C). Overexpression
of miR-3677-5p reduces mRNA and protein levels of STAT3 and
JAK1 in Hep3B and Huh-7 hepatoma cells as well as in non-
neoplastic PH5CH8 cells (Figures 1 and 4; data not shown). Very littleH5CH8) protein levels, for gp130 surface availability (Figure S5, PH5CH8) and for
e protein and luciferase signals measured for the corresponding target compared to
ash indicates that no data were obtained for this specific miRNA and target. For
is colorcoded for the protein levels in Hep3B and PH5CH8 cells (reduction depicted
ibitory effects on STAT3 activation (from the strongest to the lowest).
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cussed here, which are associated with tumor-suppressive functions,
miR-3677-5p is upregulated in HCC and an increased expression cor-
relates with poor survival,76,77 indicating a potential tumor-promot-
ing role. Of note, however, this is one of the very few miRNAs
showing divergent effects in the 2 reporter cell lines: while it reduced
luciferase activity in the Hep3B reporter cells, it increased reporter
gene activity in the first screen in Hek-293T reporter cells (see
Table S2). Clearly, this miRNA warrants further analysis.
miRNA-Mediated Effects on gp130
Finally, we identified miRNAs efficiently decreasing gp130 surface
expression. miR-16-1-3p, miR-4477, miR-520f-3p, and miR-194-5p
showed a reduction of at least 25% of gp130 surface expression. As
gp130 is the signaling receptor shared by the IL-6-type cytokines, these
miRNAs may be particularly relevant in situations requiring the inhi-
bition of various cytokines of the IL-6 family. Indeed, monotherapies
with monoclonal antibodies targeting IL-6 or IL6R have failed in clin-
ical trials against multiple myeloma,78–80 metastatic renal cell carci-
noma,81 and prostate cancer,82,83 probably due to the compensation
of the IL-6-signaling pathway by other gp130 ligands.84,85
One of the miRNAs identified here to target gp130 was also reducing
JAK1 protein levels (miR-520f-3p). Interestingly, 2 of the miRNAs
efficiently reducing gp130 surface availability (miR-16-1-3p and
miR-194-5p) caused a strong reduction of phosphorylated STAT3
(suppression of greater than 50%; Figure 1). The 2 other miRNAs
(miR-4473 and miR-520f-3p) only reduced pSTAT3 levels at least
25% compared to the control. miR-4473 and miR-520f-3p were
also less potent than miR-16-1-3p when monitoring the effects on
LBP expression, a STAT3-inducible gene (Figure 3C). Interestingly,
those 2 miRNAs also bound to SOCS3 30 UTR (Figure S7A), the ma-
jor inhibitor of IL-6 signaling, which might explain their overall
weaker effect. A careful comparison with the effects of small inter-
fering RNAs (siRNAs) specifically downregulating their target
mRNAs would allow for a further dissection of the impact of “other”
miRNA targets on the signaling readouts. However, in order to facil-
itate this comparison, doses of siRNAs would have to be adjusted to
achieve only partially suppressed levels similar to the ones obtained
with miRNAs.
miR-16-1-3p is part of a well-characterized tumor suppressor cluster
(mir-15a16-1, reviewed in Huang),86 located in the chromosomal
region 13q14.2, which is often deleted in cancer.87–90 Interestingly,
min-icells loaded with miR-16-based mimics (TargomiRs) have
entered first clinical trials for patients with malignant mesotheli-
oma.55 While many targets have been identified for miR-16-5p, its
passenger strand is less studied. Recently, it was shown to target
TWIST1 in gastric91 and non-small-cell lung92 cancer cells. To our
knowledge, no link between miR-16-1-3p and the IL-6-JAK-
STAT3-signaling pathway had been established so far.
miRNAs affecting the receptor availability may be particularly
promising candidates for further investigation (see Figure 6B),428 Molecular Therapy: Nucleic Acids Vol. 16 June 2019and they will have more specific effects than miRNAs targeting
signaling molecules shared by many cytokines. Notably, several of
the miRNAs identified to affect IL-6 signal transduction have actu-
ally multiple targets within the pathway (see Figure 6). Combina-
tions of miRNAs, either sharing the same target (gp130; Figure 3)
or regulating different signaling molecules of the pathway (gp130,
JAK1, STAT3, and/or IL6R; Figure 5) did not increase effects
compared to single treatments, indicating that drug candidates
based on a single miRNA might be able to achieve optimal signal
attenuation. However, possible saturation effects need to be ad-
dressed by detailed dose-response analyses (we used up to 60-nM
mimics for the combination treatments shown in Figures 3 and 5;
for comparison, Liang et al.93 described that transfection of
10-fold less siRNA already led to considerable AGO2 competition
of endogenous miRNAs). A more detailed analysis of miRNA
cooperation may also be warranted, considering that the spacing
between two miRNAs on the 30 UTR of a common target mRNA
may contribute to the efficiency of target mRNA downregulation.
Saetrom et al.94 have determined the optimal spacing for downregu-
lation to be between 17 and 35 nt between the seed sites.
Subsequent studies will have to evaluate the therapeutic relevance of
selected miRNAs on cellular behavior (proliferation, migration, and
invasion) as well as in the context of IL-6-dependent disease models,
in particular for inflammatory diseases (e.g., rheumatoid arthritis)
and cancer (e.g., HCC).
MATERIALS AND METHODS
Materials and Cell Culture
All cells were grown at 37C in a water-saturated atmosphere at 5%C
CO2. HEK293T, Hep3B, PH5CH8, and DU145 cells were maintained
in DMEM (Lonza, Basel, Switzerland) and A549 cells in DMEM-F12
medium (Lonza, Basel, Switzerland), both supplemented with 10%
fetal bovine serum (FBS) (Gibco, Thermo Fisher Scientific, Erembo-
degem, Belgium), 25 mM HEPES (Lonza, Basel, Switzerland), and
100 mg/mL normocin (InvivoGen, Toulouse, France). IGR39 cells
were cultured in RPMI 1640medium (Lonza, Basel, Switzerland) sup-
plemented with 10% FBS and 100 mg/mL normocin.
All miRIDIAN miRNA mimics were obtained from Dharmacon (GE
Healthcare,Diegem,Belgium).Vectors containing the30UTRsequence
of the genes coding for IL6R (GenBank: NM_181359.1), gp130
(GenBank: NM_001190981.1), JAK1 (GenBank: NM_002227.2),
SOCS3 (GenBank: NM_003955.4), and STAT3 (GenBank: NM_
213662.1) were purchased from GeneCopoeia (Tebu-Bio, Boechout,
Belgium), aswell as thebackbone vector (pEZX-MT05) is used as a con-
trol to monitor the off-target effects. Mimic transfections were per-
formed using HiPerFect Transfection Reagent (QIAGEN, Venlo, the
Netherlands) and 20 nM miRNA mimic (or control), according to
the manufacturer’s instructions. Co-transfections of 30 UTR reporter
vectors and miRNA mimics were performed using DharmaFect Duo
(Dharmacon, GE Healthcare, Diegem, Belgium), 100 ng 30 UTR re-
porter vector, and 20 nM miRNA mimic (or control), according to
the manufacturer’s protocol.
www.moleculartherapy.org2 days after mimic transfection, cells were stimulated for 24 h with
20 ng/mL hy-IL-6, a designer cytokine comprising IL-6 bound to
the extracellular domain of IL6R (sIL6R) through a flexible polypep-
tide linker.34 For Figure 5, Hep3B cells were stimulated with 20 ng/mL
IL-6 (PeproTech, Tebu-Bio, Boechout, Belgium) instead of hy-IL-6.
Engineering of Stable Cell Lines Allowing for High-Throughput
Screening of miRNAs Affecting the JAK-STAT(3)-Signaling
Pathway
HEK293T cells were plated in 6-well plates in complete medium,
and, 24 h later, they were transduced with lentiviral particles
containing 6 STAT3-responsive elements (STAT3-REs, sequence:
5-TTCTGGGAA-30), followed by a minimal cytomegalovirus
(CMV) promoter in front of the secreted Cypridina luciferase gene
and linked to a puromycin resistance gene. 48 h after transduction,
selection of transduced cells was initiated with 3 mg/mL puromycin
(InvivoGen, Toulouse, France). After several rounds of selection,
hy-IL-6 responsiveness of the construct was assessed by measuring
the Cypridina luciferase activity in the supernatant of stimulated
HEK293T-STAT3-RE-Cypridina luciferase (Cluc) cells (20 ng/mL
hy-IL-6). The transfected clone showing the highest fold induction
of luciferase activity upon cytokine treatment was selected and
amplified.
Hep3B cells (hepatoma cells with a ploidy status of n = 3.2, see
Wilkens et al.95; for mutations in cancer genes see Table S1 in
Ewald)96 were plated in 6-well plates in complete medium and trans-
fected with a linearized plasmid containing the STAT3-inducible pro-
moter rPAP135,36 in front of the secreted Cypridina luciferase gene,
using the PromoFectin-Hepatocyte reagent (PromoCell, Bio-Con-
nect, Huissen, the Netherlands), following the manufacturer’s proto-
col. 4 h later, serum-reduced Optim-MEM medium (Life Technolo-
gies, Merelbeke, Belgium) was replaced by normal DMEM. After
4 days, selection of transfected cells was initiated with 500 mg/mL
G418 (Sigma-Aldrich, Diegem, Belgium). After several rounds of
selection, a pool of Hep3B-rPAP1-Cluc cells was tested for successful
inducible luciferase production and secretion upon stimulation with
20 ng/mL hy-IL-6 (Figure S2B) and amplified.
Selection of miRNAs for the Pre-screen
We designed a library consisting of 538 miRNAs, which were selected
from miRBase version (v.)21 by the following criteria: (1) presence in
the high-confidence list from miRBase,97 (2) predicted by Diana web
server v.5.098,99 to target molecule(s) related to IL-6 signaling, (3)
presence in the top 100 list of miRNAs regulated upon hy-IL-6 stim-
ulation in primary hepatocytes (microarray analysis, ArrayExpress:
E-MTAB-6572),100 and (4) miRNAs previously published as regu-
lated by STAT3 (for a complete list, see Table S1).
Luciferase Reporter Gene Assays
For the miRNA library screens, 104 HEK293T-STAT3-RE-Cluc or
Hep3B-rPAP1-Cluc engineered cells were reverse transfected on a
96-well plate with 20 nM of the respective miRIDIANmiRNAmimic
using HiPerFect Transfection Reagent (QIAGEN, Venlo, theNetherlands). 48 h after transfection, cells were stimulated for 24 h,
as described in the figure legends, after which supernatants were
collected and kept at20C until measurement. Briefly, 10 mL super-
natant was used to measure the secreted Cypridina luciferase
activity using the BioLux Cypridina Luciferase assay kit (New
England Biolabs, Bioke, Leiden, the Netherlands), following
the manufacturer’s instructions. Automatic injection of substrate
and measurement were performed with the CLARIOstar plate
reader (BMG Labtech, ISOGEN Life Science, De Meern, the
Netherlands).
For the identification of IL6R, gp130, JAK1, SOCS3, and STAT3 as
potential target(s) of selected miRNA mimics, 104 HEK293T cells
were plated on a 96-well plate and co-transfected the next day with
a mimic and either the backbone vector or a vector containing the
Gaussia luciferase gene followed by (a portion of) the 30 UTR
sequence of IL6R (IL6Ra or b), gp130 (gp130a, b, or c), JAK1,
SOCS3, or STAT3. After 2 days of transfection, cell supernatants
were collected to assess the activities of both the secreted Gaussia
luciferase and the secreted Alkaline phosphatase, used for normaliza-
tion purposes, using the Secrete-pair dual luminescence assay kit
(GeneCopoeia, Tebu-Bio, Boechout, Belgium), according to the
manufacturer’s protocol. Both activities were determined with the
CLARIOstar plate reader. For all luciferase experiments, at least 3
independent biological replicates, each with 3 technical replicates,
were performed.
Cell Viability Assessment
To monitor the effects of the miRNA mimics on cell growth (and
thereby reduce false-positive results), cell viability was assessed
for the same wells as the luciferase measurements using the
PrestoBlue reagent (Invitrogen, Thermo Fisher Scientific, Erembode-
gem, Belgium), according to the manufacturer’s instructions. The
fluorescence of each well was then measured with the CLARIOstar
plate reader and normalized to the fluorescence emitted by the cells
treated with HiPerFect transfection reagent only, present on each
plate.
Flow Cytometry
The effects of miRNA mimics on gp130 receptors were assessed by
flow cytometry. Briefly, transfected cells were resuspended in cold
PBS supplemented with 5% FBS and 0.1% sodium azide (Sigma-
Aldrich, Diegem, Belgium) and incubated with 0.5 mg antibody
against gp130 (555757, BD Biosciences, Erembodegem, Belgium) or
the corresponding isotype control antibody, immunoglobulin G
(IgG)2a (21225021, Immunotools, Friesoythe, Germany), for 1 h
at 4C. Cells were then washed with cold PBS-azide and incu-
bated with secondary labeled antibodies (715-116-150, Jackson
ImmunoResearch Laboratories, Bio-Connect, Huissen, the
Netherlands). After 1 h of incubation at 4C, cells were again washed
with cold PBS-azide and then analyzed on a FACSCanto II flow
cytometer using the FACSDiva software (BD Biosciences, Erembode-
gem, Belgium). Overlay plots were created using the FlowJo software
(FlowJo, Ashland, OR).Molecular Therapy: Nucleic Acids Vol. 16 June 2019 429
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Cultured cells were lysed on the plate with ice-cold Laemmli 1
buffer and kept at 20C. Before separation by SDS-PAGE and blot-
ting either onto a polyvinylidene fluoride (PVDF)-PSQ (for LI-COR)
or a PVDF-FL (for enhanced chemiluminescence [ECL]) membrane
(Millipore, Overijse, Belgium), protein extracts were heated for
10 min at 96C. Blots were incubated overnight with antibodies
against human JAK1 (610232, BD Biosciences, Erembodegem,
Belgium), STAT3 (610189, BD Biosciences, Erembodegem, Belgium),
pSTAT3 (9145, Cell Signaling Technology, Bioke, Leiden, the
Netherlands), or Vinculin (13901, Cell Signaling Technology, Bioke,
Leiden, the Netherlands). After washing, membranes were incubated
for 1 h at room temperature with either fluorescent (LI-COR Biosci-
ences, Westburg, Leusden, the Netherlands) or horseradish peroxi-
dase (HRP)-conjugated secondary antibodies (Cell Signaling
Technology, Bioke, Leiden, the Netherlands) for LI-COR or ECL
detection, respectively. Prior to ECL detection, membranes were incu-
bated in an ECL solution containing 2.5 mM luminol, 2.6 mM
hydrogen peroxide, 100 mM Tris/HCl (pH 8.8), and 0.2 mM para-
coumaric acid.101 Signals were detected with the Odyssey classic
(LI-COR Biosciences,Westburg, Leusden, the Netherlands) or Fusion
SL device (Vilber, Analis, Suarlee, Belgium). Protein levels were quan-
tified by using the Image Studio Lite software (version 5.2, LI-COR
Biosciences, Lincoln, NE) and normalized to the total protein content
(REVERT Total Protein Stain, LI-COR Biosciences, Westburg, Leus-
den, the Netherlands), following the manufacturer’s instructions.
Total RNA Isolation and qPCR
Total RNA was extracted using the Quick-RNA MiniPrep Kit (Zymo
Research, Laborimpex, Brussels, Belgium) and reverse transcribed
with the miScript II RT kit (QIAGEN, Venlo, the Netherlands) in a
volume of 10 mL, according to the respective manufacturer’s instruc-
tions. Real-time qPCR was carried out on a CFX384 Detection System
(Bio-Rad, Temse, Belgium), using 5- or 50-ng (miRNA or mRNA
detection, respectively) RNA input in a 10-mL reaction volume, 2
iTaq SYBR Green Supermix (Bio-Rad, Temse, Belgium), and 1 mL
10 miRNA-specific primers (QIAGEN, Venlo, the Netherlands)
or either 2.5 pmol gene-specific primer pairs or 1 mL 10QuantiTech
primers (QIAGEN, Venlo, Netherlands). miRNAs and mRNAs of in-
terest, as well as small RNAs used as miRNA normalizers (RNU1A,
SCARNA17, and SNORD95) and reference genes used for RNA
normalization (HRPT, PPIA, and TBP), were assessed in parallel
for each sample and run in triplicates. Calculations were carried out
by using the CFX Manager software (Bio-Rad, Temse, Belgium) pro-
vided with the machine.
Primers were purchased from Eurogentec (Liège, Belgium) and the se-
quences were as follows: IL6R forward, 50-GTATTCCCAGGAGTCC
CAGA-30; IL6R reverse, 50-GCAAGATTCCACAACCCTG-30; gp130
forward, 50-TGAAACTGCTGTGAATGTGG-30; gp130 reverse,
50-CATCCTTCCCACCTTCATCT-30; HPRT forward, 50-TGGA
CAGGACTGAACGTCTT-30; HPRT reverse, 50-GAGCACACAGA
GGGCTACAA-30; JAK1 forward, 50-TCTTGGAATCCAGTGGAGG
CATAAA-30; JAK1 reverse, 50-CACTCTTCCCGGATCTTGTTTT430 Molecular Therapy: Nucleic Acids Vol. 16 June 2019TCT-30; LBP forward, 50-AGGTGATGTTTAAGGGTGAAAT-30;
LBP reverse, 50-ATAATCCGAGATGGCAAAGTA-30; PPIA forward,
50-CAGACAAGGTCCCAAAGACA-30; PPIA reverse, 50-CCATTA
TGGCGTGTGAAGTC-30; SOCS3 forward, 50-ATGAGAACTGC
CAGGGAATC-30; SOCS3 reverse, 50-CCCAGGCTCCACAAC
CA-30; STAT3 forward, 50-ACACAGATAAACTTGGTCTTCAG
GTA-30; STAT3 reverse, 50-GCCAGAGAGCCAGGAGCA-30; TBP
forward, 50-ACCCAGCAGCATCACTGTT-30; and TBP reverse,
50-CGCTGGAACTCGTCTCACTA-30.
Statistical Analysis
Statistical significance between control (NCM1) and the candidate
miRNA for western blot analysis (Figures 1 and 4) and luciferase
assays (Figures 2, 4, S4, and S7) was assessed by non-parametric
one-way ANOVA (Kruskal-Wallis test), followed by Dunn’s multiple
comparisons test performed with the statistical program Prism 7
(GraphPad, La Jolla, CA, USA).
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